dr. elizabeth plimack on ipilimumab and pd-l1 inhibitors in the treatment of bladder cancer
Published 8 years ago • 72 plays • Length 0:51Download video MP4
Download video MP3
Similar videos
-
4:15
dr. elizabeth plimack on a hypomethylating agent plus anti-pd-l1 for muc after disease progression
-
1:20
dr. galsky on the role of ipilimumab for the treatment of bladder cancer
-
0:49
dr. elizabeth plimack on immunotherapy potential in bladder cancer
-
1:44
dr. plimack on a phase ib study of pembrolizumab in bladder cancer
-
1:00
dr. plimack on the growth of immunotherapy in bladder cancer
-
1:14
dr. plimack on second-line checkpoint inhibitors in bladder cancer
-
26:20
management of non-muscle invasive bladder cancer
-
1:13
bladder cancer
-
3:13
doctor reviews how stem cells are changing the medical industry forever
-
7:06
pd-l1 in metastatic bladder cancer - bladder cancer video library
-
28:47
pediatric trk fusion-positive cancer: optimizing care with trk inhibitors
-
0:47
dr. plimack on the challenges with available immunotherapies for bladder cancer
-
1:35
dr. plimack on choosing a checkpoint inhibitor in bladder cancer
-
1:09
dr. galsky on the role of ipilimumab in bladder cancer
-
11:04
bladder cancer - overview (types, pathophysiology, diagnosis, treatment)
-
1:04
dr. plimack on immunotherapy combinations in bladder cancer
-
1:39
dr. elizabeth plimack on nivolumab in kidney cancer
-
1:18
dr. plimack on combo of pembrolizumab/epacodostat in bladder cancer
-
1:27
dr. elizabeth plimack on consideration regarding nivolumab in rcc
-
1:09:47
evidence and insights on innovative treatment for bladder cancer
-
1:03:24
bladder cancer: understanding immune-, targeted-, and antibody-based models for patient care
-
7:55
pd-l1 expression in bladder cancer